TNGX הכנסה נקייה של החברה tangotx.com

This chart reflects the current market value of Tango Therapeutics (TNGX) at -0.12. The current trend is supported by the initial success of selective PRMT5 inhibitors in treating solid tumors. The company's strategy relies on the concept of synthetic lethality and targeting various genetic markers to minimize pipeline losses. Business success is tied to regulatory approvals, human capital, and general advancements in oncology.

Profit reflects the actual operating income of Tango Therapeutics (TNGX), stripped of GAAP accounting adjustments. By analyzing the company's profit dynamics, an investor determines the business's actual ability to generate cash flow. This metric is calculated by offsetting daily inflows against current expenses. For Tango Therapeutics (TNGX), this metric is critical, as the success of synthetic lethality in oncology depends on molecular efficacy. The upward trend of the curve confirms the commercial viability of the patents.